Somerset Tianhong completed tens of millions of yuan in B+ round of financing

Recently, Tianhong Somerset completed tens of millions of yuan in B+ round of financing. This round of financing was jointly invested by Qiao Jing Capital and Zhuo Pu Capital. The financing amount will be used for the marketing of the company’s iliac vein stent and the research and development of follow-up products to promote the creation of veins. One-stop solution for disease treatment.

As a one-stop product platform in the field of venous disease treatment, Tianhong Somerset has a comprehensive layout in the treatment of peripheral venous stenosis and obstruction, thrombosis and venous return disorders. In April 2022, the Venastent® iliac vein stent developed by Tianhong Somerset was approved by the State Food and Drug Administration for marketing, which is the first domestic iliac vein stent approved for marketing in China. At present, the Venastent® iliac vein stent has been installed in more than ten provinces and cities across the country, and it is highly evaluated for clinical first-line use.

Somerset Tianhong is the first company in my country that focuses on the treatment of peripheral venous diseases. The company has obtained 6 NMPA product registration certificates including iliac vein stent system, peripheral balloon dilatation catheter, peripheral vascular high pressure balloon dilatation catheter, intravascular foreign body removal device, saphenous vein stripping catheter, and balloon inflation device, and All have independent intellectual property rights. At the same time, Tianhong Shengjie is also developing product lines such as thrombosis therapy, drug-device combination, and vascular interventional embolization.

At present, Tianhong Somerset has applied for 55 domestic patents and authorized 40, including 7 authorized invention patents, 31 authorized utility model patents, and 2 authorized design patents; applied for 7 international patents in the United States, Europe, Japan, etc. 3 items have been authorized.

In the future, Somerset will continue to improve its venous intervention product line around peripheral venous obstruction, stenosis, thrombosis, reflux and other diseases. At the same time, the company’s industrial layout will extend to peripheral arteries and peripheral blood vessels, and the product category will also change from access-type products to drug-device combination and functional products. In addition, Somerset Tianhong will start from treatment and gradually cover the whole process of screening, diagnosis, treatment and prognosis.